Evidence map›Paper›PMID 37399496›Full record

ArticleAmerican journal of physiology. Cell physiology2023

Cellular microRNAs target SARS-CoV-2 spike protein and restrict viral replication.

Kishore Vaddadi, Chaitanya Gandikota, Chaoqun Huang, Yurong Liang, Lin Liu

Abstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kishore VaddadiOklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, Oklahoma, United States.ORCID 0000-0003-0320-9064
Chaitanya GandikotaOklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, Oklahoma, United States.
Chaoqun HuangOklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, Oklahoma, United States.
Yurong LiangOklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, Oklahoma, United States.
Lin LiuOklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, Oklahoma, United States.ORCID 0000-0002-4811-4897

Funding

ZFC3H1 Regulation of Host Defense and Influenza A Virus PathogenesisP20GM103648 · NIGMS · OKLAHOMA STATE UNIVERSITY STILLWATER · PI CHANNAPPANAVAR, RUDRAGOUDA · 2013 to 2022
$22.3M
The Role of LncRNAs in Pulmonary FibrosisR01HL135152 · NHLBI · OKLAHOMA STATE UNIVERSITY STILLWATER · PI LIU, LIN · 2017 to 2020
$1.5M
Lnc-PINK regulation of innate immunity in lung epithelial cellsR21AI152004 · NIAID · OKLAHOMA STATE UNIVERSITY STILLWATER · PI LIU, LIN · 2021 to 2022
$411k
NHLBI NIH HHS R01 HL135152NIAID NIH HHS R21 AI152004NIGMS NIH HHS P20 GM103648
6 · The paper itself

Abstract

MicroRNAs (miRNAs) regulate gene expression posttranscriptionally and are implicated in viral replication and host tropism. miRNAs can impact the viruses either by directly interacting with the viral genome or modulating host factors. Although many miRNAs have predicted binding sites in the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral RNA genome, little experimental validation has been done. We first identified 492 miRNAs that have binding site(s) on the spike (S) viral RNA by a bioinformatics prediction. We then validated the selected 39 miRNAs by examining S-protein levels after coexpressing the S-protein and a miRNA into the cells. Seven miRNAs were found to reduce the S-protein levels by more than 50%. Among them, miR-15a, miR-153, miR-298, miR-508, miR-1909, and miR-3130 also significantly reduced SARS-CoV-2 viral replication. SARS-CoV-2 infection decreased the expression levels of miR-298, miR-497, miR-508, miR-1909, and miR-3130, but had no significant effects on miR-15a and miR-153 levels. Intriguingly, the targeting sequences of these miRNAs on the S viral RNA showed sequence conservation among the variants of concern. Our results suggest that these miRNAs elicit effective antiviral defense against SARS-CoV-2 by modulating S-protein expression and are likely targeting all the variants. Thus, the data signify the therapeutic potential of miRNA-based therapy for SARS-CoV-2 infections.

Indexed as

COVID-19MicroRNAsAntiviral AgentsHumansRNA, ViralSARS-CoV-2Spike Glycoprotein, CoronavirusVirus ReplicationAntiviral AgentsMicroRNAsMIRN153 microRNA, humanMIRN298 microRNA, humanMIRN497 microRNA, humanRNA, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2microRNAsSARS-CoV-2spikevariants of concernvirus replication

Identifiers

PMID37399496
PMCPMC10390048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.